Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 2 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 2 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular fluid volume, acid-base balance, and nerve impulse transmission. Dextrose provides caloric supplementation and sodium chloride maintains extracellular fluid volume and electrolyte balance. The combination corrects electrolyte and fluid deficits.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion; dose depends on serum potassium levels and body weight. Typical adult maintenance: 10-20 mEq/hour, not exceeding 40 mEq/hour or 200 mEq/day. Concentration used: 0.3% potassium chloride (40 mEq/L) in D5 0.2% NaCl.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Potassium: 2-4 hours (plasma, no true terminal t½ due to rapid equilibration with intracellular stores); clinical context: half-life prolonged in renal impairment.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Renal: potassium >90% excreted in urine (glomerular filtration, distal tubular secretion); chloride 95% renally; dextrose nearly completely reabsorbed; sodium >99% renally with reabsorption.
Category C
Category A/B
Electrolyte
Electrolyte